Pfizer Inc. (PFE)
After hours:
| Previous close | 54.27 |
| Open | 53.78 |
| Bid | 0.00 x 3100 |
| Ask | 0.00 x 1000 |
| Day's range | 51.25 - 53.89 |
| 52-week range | 33.36 - 55.70 |
| Volume | |
| Avg. volume | 33,287,232 |
| Market cap | 288.951B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 14.70 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.56 (2.87%) |
| Ex-dividend date | 04 Nov 2021 |
| 1y target est | N/A |
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, November 24, 2021--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.
- Business Wire
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
NEW YORK & MAINZ, Germany, November 22, 2021--Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies’ pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the secon
- Business Wire
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
NEW YORK & MAINZ, Germany, November 19, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.
